SymBio Pharmaceuticals Limited revised earnings guidance for the fiscal year ending December 31, 2024. For the year, the company now expects net sales to be JPY 2,623 million, operating loss to be JPY 3,702 million, loss attributable to owner of parent to be JPY 3,628 million or JPY 84.15 loss per share against net sales to be JPY 3,641 million, operating loss to be JPY 2,837 million, loss attributable to owner of parent to be JPY 2,870 million or JPY 71.93 loss per share previous guidance for the same period. As a result of the impact of the significant decrease in gross profit due to the decline in net sales, the company has revised its forecasts.